News | April 06, 2022
ENTOD Pharma bullish on Macushield sales
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Resolv ER may remedy leading causes of blindness in adults
Key takeaways of recent quarter & conference call highlights
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India business is growing as per projections; whereas US business will bounce back soon.
Subscribe To Our Newsletter & Stay Updated
